Back to Cardiology
Cardiologyv2016 GunesEvidence-Based

Infective Endocarditis (IE) Mortality Risk Score

Predicts 6-month mortality in patients with infective endocarditis using validated clinical parameters. This risk stratification tool was developed from the International Collaboration on Endocarditis (ICE) Prospective Cohort Study and helps clinicians assess prognosis and guide treatment decisions in patients with definite infective endocarditis. The score incorporates host factors, IE characteristics, and complications to provide mortality risk prediction.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
mortality probability
—%
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Infective Endocarditis (IE) Mortality Risk Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Score = sum of all parameter points; Probability of 6-month mortality (%) = 100 × [1 / (1 + exp(-(2.416×score + 0.109×score² - 4.849)))]

Clinical Pearls & Practice Notes

  • Developed from the International Collaboration on Endocarditis (ICE) Prospective Cohort Study (2000-2006, n=4049)
  • Validated in external cohort with good discrimination (R² = 0.91-0.97)
  • Score ≥8 has sensitivity 86.7%, specificity 50.8%, NPV 86% for 6-month mortality
  • Surgery is associated with lower mortality but performed less frequently in highest risk patients
  • Six-month mortality after IE is approximately 25% overall
  • Should be used in conjunction with clinical judgment and multidisciplinary team assessment
  • Does not replace individual clinical decision-making regarding surgical timing
  • Score incorporates host factors, IE characteristics, and complications
  • Negative points for longer symptom duration and viridans group strep (better prognosis)
  • Positive points for advanced age, dialysis, nosocomial IE, and complications
  • Persistent bacteremia defined as continued positive blood cultures despite appropriate antibiotics
  • Paravalvular complications include abscess, fistula, or pseudoaneurysm formation
  • NYHA Class 3-4 heart failure indicates severe cardiac compromise

Evidence & Literature Citations

  1. Gunes M, Gecmen C, Beker Evans M, et al. Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis. J Am Heart Assoc. 2017 Apr 7;6(4):e003016. doi: 10.1161/JAHA.115.003016.
  2. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009 Mar 9;169(5):463-73. doi: 10.1001/archinternmed.2008.603.
  3. Cahill TJ, Baddour LM, Habib G, et al. Challenges in Infective Endocarditis. J Am Coll Cardiol. 2017 Jul 25;70(3):325-335. doi: 10.1016/j.jacc.2017.06.007.

Score Interpretation Ranges

Low Risk0 – 10 pts

Mortality probability ≤10%

Moderate Risk10 – 25 pts

Mortality probability 10-25%

High Risk25 – 50 pts

Mortality probability 25-50%

Very High Risk50 – 100 pts

Mortality probability >50%

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.